Literature DB >> 28449622

Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?

Kashif M Munir1, Elizabeth M Lamos1.   

Abstract

Entities:  

Keywords:  Alogliptin; dipeptidyl peptidase −4 inhibitor; linagliptin; saxagliptin; sitagliptin

Year:  2017        PMID： 28449622     DOI： 10.1080/14656566.2017.1323878

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  5 in total

Review 1.  The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect.

Authors:  Konstantinos Makrilakis
Journal:  Int J Environ Res Public Health       Date:  2019-07-30       Impact factor: 3.390

2.  Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial.

Authors:  Xiao-Jun Zhou; Lin Ding; Jia-Xin Liu; Le-Qun Su; Jian-Jun Dong; Lin Liao
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

3.  Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.

Authors:  Hae Jin Kim; Young Sik Kim; Chang Beom Lee; Moon-Gi Choi; Hyuk-Jae Chang; Soo Kyoung Kim; Jae Myung Yu; Tae Ho Kim; Ji Hyun Lee; Kyu Jeung Ahn; Kyoungmin Kim; Kwan Woo Lee
Journal:  Diabetes Ther       Date:  2019-05-11       Impact factor: 2.945

Review 4.  Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.

Authors:  Ashok K Das; Pramod Gandhi; Banshi Saboo; Sanjay Reddy; Rajeev Chawla; Abdul Hamid Zargar; Rajiv Kovil; Manoj Chawla; S K Sharma; Sunil Gupta; B M Makkar; Vinod Mittal; Soumik Goswami; S R Arvind; Shalini Jaggi; Sarita Bajaj; Sambit Das
Journal:  J Family Med Prim Care       Date:  2021-12-27

Review 5.  New Aspects of Diabetes Research and Therapeutic Development.

Authors:  Leslie S Satin; Scott A Soleimanpour; Emily M Walker
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.